Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh (VRTX34) Stock Price & Analysis

VRTX34 Stock Chart & Stats

R$94.95R$6.63(7.51%)

At close: Oct 30

Day’s Range: BRL 94.20 - BRL 95.11
52-Week Range: BRL 60.00 - BRL 95.11
Previous Close: BRL 88.32
Volume: N/A
Average Volume (3M): 260
Market Cap: BRL 770.61B
Enterprise Value: BRL 49.22B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 12484.9
Beta: -0.48
Next Earnings: Nov 02, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh News

Vertex: Kidney Franchise Confidence Strengthened; Buy Rating Reiterated with Unchanged $641 Price Target

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals, retaining the price target of $641.00. Andrew Fein has given his Buy rating due to a combination

6d agoVRTX VX1

Vertex Renal Franchise Strength, Clinical Data, and Payer Tailwinds Support Unchanged $667 Price Target and Maintained Buy Rating

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Vertex Pharmaceuticals. The associated price target remains the same with $667.00. Tazeen Ahmad has given his

6d agoVRTX VX1

Vertex Buy Rating Reaffirmed as Analyst Sees Multi-Blockbuster Renal Opportunity and Maintains $615 Price Target

UBS analyst Michael Yee maintained a Buy rating on Vertex Pharmaceuticals on October 24 and set a price target of $615.00. Michael Yee has given his Buy rating due to

1w agoVRTX VX1

Vertex Pharmaceuticals price target lowered to $667 from $672 at BofA

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $667 from $672 and keeps a Buy rating on the shares after updating estimates ahead of the company’s Q3

2w agoVRTX VX1

Vertex Pharmaceuticals to present data on Alyftrek at NACFC

Vertex Pharmaceuticals (VRTX) announced new interim data from the ALYFTREK 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age

3w agoVRTX VX1

Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $576 from $570 and keeps an Outperform rating on the shares as part of a broader research note

3w agoVRTX VX1

Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Pune, India, October 6th, 2026, FinanceWire This is a paid advertisement. Quantum BioPharma Ltd. (NASDAQ:QNTM) (FRA: 0K91) has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business

3w agoBBIO KRYS

Vertex Pharmaceuticals price target raised to $615 from $585 at UBS

UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $585 and keeps a Buy rating on the shares. Vertex’s key near-term catalyst is the early-2027 Phase

1M agoVRTX VX1

Vertex Pharmaceuticals price target raised to $615 from $585 at UBS

UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $585 and keeps a Buy rating on the shares. Vertex’s key near-term catalyst is an early-2027 interim

1M agoVRTX VX1

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

Vertex Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a Buy rating on the stock and has a

1M agoVRTX VX1

Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated

Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Tazeen Ahmad has given his Buy rating due to a

1M agoVRTX VX1

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data supports a

1M agoMAZE VRTX

Maze jumps 25% to $27.99 after Vertex kidney disease data

10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s

1M agoMAZE VRTX

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease – AMKD – and modest proteinuria and

1M agoVRTX VX1

VRTX34 FAQ

What was Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s price range in the past 12 months?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh lowest stock price was R$60.00 and its highest was R$95.11 in the past 12 months.

What is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s market cap?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s market cap is R$770.61B.

When is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s earnings last quarter?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh released its earnings results on Aug 03, 2026. The company reported R$0.005 earnings per share for the quarter.

Is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh pay dividends?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh does not currently pay dividends.

What is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s EPS estimate?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh have?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh has 8,110,749,500 shares outstanding.

What happened to Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s price movement after its last earnings report?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh reported an EPS of R$0.005 in its last earnings report. Following the earnings report the stock price went up 2.225%.

Which hedge fund is a major shareholder of Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh?

Currently, no hedge funds are holding shares in BR:VRTX34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh (VRTX34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	14	2	6
Technical Analysis	2	2	6
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to BR:VRTX34
Company	Price & Change	Follow
BR:BMYB34Bristol-Myers Squibb Company Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
BR:G1SK34GSK PLC ADR Unsponsored Brazilian Depositary Receipt Repr 0.2 ADR
BR:GILD34Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh
BR:PFIZ34Pfizer Inc Shs Unsponsored Brazilian Depository Receipts Repr 0.25 Sh
BR:REGN34Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh

Compare BR:VRTX34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

VRTX34 Stock Chart & Stats

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh News

Vertex: Kidney Franchise Confidence Strengthened; Buy Rating Reiterated with Unchanged $641 Price Target

Vertex Renal Franchise Strength, Clinical Data, and Payer Tailwinds Support Unchanged $667 Price Target and Maintained Buy Rating

Vertex Buy Rating Reaffirmed as Analyst Sees Multi-Blockbuster Renal Opportunity and Maintains $615 Price Target

Vertex Pharmaceuticals price target lowered to $667 from $672 at BofA

Vertex Pharmaceuticals to present data on Alyftrek at NACFC

Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital

Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Vertex Pharmaceuticals price target raised to $615 from $585 at UBS

Vertex Pharmaceuticals price target raised to $615 from $585 at UBS

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Maze jumps 25% to $27.99 after Vertex kidney disease data

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

VRTX34 FAQ

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh (VRTX34) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium